• Consensus Rating: Buy
  • Consensus Price Target: $12.60
  • Forecasted Upside: 60.71%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.84
▲ +0.22 (2.89%)

This chart shows the closing price for LFMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LifeMD Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LFMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LFMD

Analyst Price Target is $12.60
▲ +60.71% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for LifeMD in the last 3 months. The average price target is $12.60, with a high forecast of $15.00 and a low forecast of $10.00. The average price target represents a 60.71% upside from the last price of $7.84.

This chart shows the closing price for LFMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in LifeMD. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/21/2024B. RileyReiterated RatingBuy ➝ Buy$12.00Low
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
5/9/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$13.00 ➝ $15.00Low
4/23/2024BTIG ResearchBoost TargetBuy ➝ Buy$13.00 ➝ $14.00Low
3/15/2024BTIG ResearchBoost TargetBuy ➝ Buy$11.00 ➝ $13.00N/A
1/11/2024HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $12.00Low
12/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$9.00Low
12/1/2023B. RileyReiterated RatingBuyLow
11/30/2023Craig HallumInitiated CoverageBuy$10.00Low
11/14/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$8.00 ➝ $9.00Low
11/9/2023HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $10.00Low
10/2/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$7.00 ➝ $8.00Low
9/14/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00Low
7/21/2023Cantor FitzgeraldInitiated CoverageOverweight$7.00Low
7/10/2023B. RileyBoost Target$3.50 ➝ $7.00Low
7/3/2023HC WainwrightInitiated CoverageBuy$9.00Low
3/23/2023BTIG ResearchLower TargetBuy$8.00 ➝ $7.00Low
5/16/2022BTIG ResearchLower TargetNA$8.00N/A
5/16/2022B. RileyLower Target$16.00 ➝ $8.00High
3/22/2022Colliers SecuritiesReiterated RatingBuyMedium
3/10/2022Colliers SecuritiesInitiated CoverageBuy$14.00High
11/11/2021BTIG ResearchLower TargetBuy$30.00 ➝ $15.00High
10/4/2021B. RileyReiterated RatingBuy$16.00Medium
8/13/2021BTIG ResearchLower TargetBuy$35.00 ➝ $30.00High
7/19/2021BTIG ResearchLower TargetPositive ➝ Buy$43.00 ➝ $35.00Medium
6/8/2021BTIG ResearchReiterated RatingBuy$40.00High
2/18/2021BTIG ResearchBoost TargetPositive ➝ Buy$15.00 ➝ $40.00Low
2/5/2021B. RileyInitiated CoverageBuy$35.00Low
1/6/2021BTIG ResearchInitiated CoverageBuy$15.00N/A
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/28/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/27/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 3 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2024

Current Sentiment

  • 3 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
LifeMD logo
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
Read More

Today's Range

Now: $7.84
Low: $7.61
High: $8.08

50 Day Range

MA: $10.18
Low: $7.62
High: $12.51

52 Week Range

Now: $7.84
Low: $1.93
High: $12.88

Volume

657,600 shs

Average Volume

848,541 shs

Market Capitalization

$331.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Frequently Asked Questions

What sell-side analysts currently cover shares of LifeMD?

The following sell-side analysts have issued reports on LifeMD in the last year: B. Riley, BTIG Research, Cantor Fitzgerald, Craig Hallum, and HC Wainwright.
View the latest analyst ratings for LFMD.

What is the current price target for LifeMD?

5 Wall Street analysts have set twelve-month price targets for LifeMD in the last year. Their average twelve-month price target is $12.60, suggesting a possible upside of 60.7%. Cantor Fitzgerald has the highest price target set, predicting LFMD will reach $15.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $10.00 for LifeMD in the next year.
View the latest price targets for LFMD.

What is the current consensus analyst rating for LifeMD?

LifeMD currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LFMD will outperform the market and that investors should add to their positions of LifeMD.
View the latest ratings for LFMD.

What other companies compete with LifeMD?

How do I contact LifeMD's investor relations team?

LifeMD's physical mailing address is 800 THIRD AVENUE SUITE 2800, NEW YORK NY, 10022. The company's listed phone number is (866) 351-5907 and its investor relations email address is [email protected]. The official website for LifeMD is www.lifemd.com. Learn More about contacing LifeMD investor relations.